secwatch.observer — SEC 8-K summary
======================================

Issuer:     HCW Biologics Inc. (HCWB)
CIK:        0001828673
Form:       8-K
Filed at:   2025-10-16T23:59:59+00:00
Accession:  0001193125-25-240890
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Nasdaq grants HCW Biologics extension to regain compliance by Dec 31, 2025
--------------------------------------------------------------------------

- Nasdaq Hearings Panel granted extension to demonstrate compliance with Equity Rule by Dec 31, 2025, and all listing rules by Feb 16, 2026.
- Company was non-compliant with Listing Rule 5550(b)(1) (minimum stockholders' equity) as of June 30, 2025.
- Hearing held September 25, 2025; Panel considered Company's compliance plan.
- Company must timely file Form 10-Q for Q3 and notify Nasdaq of significant events during exception period.
- Panel may review its decision within 45 calendar days after written decision.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828673/000119312525240890/0001193125-25-240890-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828673/000119312525240890/hcwb-20251013.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-240890

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer